Kilitch Drugs (India) Limited (NSE:KILITCH)
India · Delayed Price · Currency is INR 139.00
+0.65 (0.47%)
Apr 2, 2026, 3:29 PM IST
Kilitch Drugs (India) Revenue
Kilitch Drugs (India) had revenue of 538.08M INR in the quarter ending December 31, 2025, a decrease of -4.20%. This brings the company's revenue in the last twelve months to 2.07B, up 13.85% year-over-year. In the fiscal year ending March 31, 2025, Kilitch Drugs (India) had annual revenue of 1.98B with 28.47% growth.
Revenue (ttm)
2.07B
Revenue Growth
+13.85%
P/S Ratio
2.30
Revenue / Employee
11.07M
Employees
187
Market Cap
4.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.98B | 439.46M | 28.47% |
| Mar 31, 2024 | 1.54B | 147.74M | 10.58% |
| Mar 31, 2023 | 1.40B | 253.65M | 22.20% |
| Mar 31, 2022 | 1.14B | 457.11M | 66.71% |
| Mar 31, 2021 | 685.23M | 152.03M | 28.51% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.60B |
| Nectar Lifesciences | 16.70B |
| Windlas Biotech | 8.68B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.85B |
| Jagsonpal Pharmaceuticals | 2.82B |
| Sakar Healthcare | 2.31B |
Kilitch Drugs (India) News
- 1 year ago - Kilitch Drugs India shares surge over 2% as company invests $200,000 in Kilitch Estro Biotech - Business Upturn